Skip to main content
. 2017 Mar 3;174(8):689–699. doi: 10.1111/bph.13730

Figure 1.

Figure 1

PMX205 concentrations in the brain and spinal cord of hSOD1G93A and WT mice alongside a BBB and BSB permeability analysis. hSOD1G93A and WT mice were injected i.v. with the selective C5a1 receptor antagonist PMX205 at four different stages of disease progression (1 mg·kg−1). (A–C) Plasma, brain and spinal cord PMX205 levels at pre‐symptomatic (PS; P30), onset (OS; P70), mid‐symptomatic (MS; P130) and end‐stage (ES; P150) in WT and hSOD1G93A mice (n = 5). *P < 0.05, significantly different from WT; Student's t‐test at each stage. (D, E) BBB and BSB permeability in WT and hSOD1G93A mice at OS, MS and ES (n = 4). *P < 0.05, significantly different from WT; Student's t‐test at each stage. hSOD1G93A and WT mice were also orally dosed with PMX205 at 91 days of age over a period of 5 days (9 mg·kg−1·day−1). (F) PMX205 levels in plasma, brain and spinal cord after this oral dosing in WT and hSOD1G93A mice (n = 5). *P < 0.05, significantly different from WT; Student's t‐test for each tissue. The red line indicates the IC50, 16.7 ng·mL−1. Data are expressed as mean ± SEM.